NASDAQ:SUPN - Supernus Pharmaceuticals Stock Price, Forecast & News

Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN."

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) announced its earnings results on Tuesday, November, 5th. The specialty pharmaceutical company reported $0.54 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.59 by $0.05. The specialty pharmaceutical company had revenue of $102.14 million for the quarter, compared to analyst estimates of $108.70 million. Supernus Pharmaceuticals had a return on equity of 21.02% and a net margin of 25.92%. The firm's revenue for the quarter was down .8% on a year-over-year basis. During the same period last year, the firm earned $0.52 earnings per share. View Supernus Pharmaceuticals' Earnings History.

Supernus Pharmaceuticals updated its FY 2020 After-Hours earnings guidance on Tuesday, February, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $360-390 million, compared to the consensus revenue estimate of $407.73 million.

7 brokers have issued 12-month target prices for Supernus Pharmaceuticals' stock. Their forecasts range from $23.00 to $65.00. On average, they expect Supernus Pharmaceuticals' stock price to reach $47.33 in the next year. This suggests a possible upside of 106.3% from the stock's current price. View Analyst Price Targets for Supernus Pharmaceuticals.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Supernus Pharmaceuticals in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Supernus Pharmaceuticals.

Media stories about SUPN stock have been trending extremely negative recently, according to InfoTrie. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Supernus Pharmaceuticals earned a media sentiment score of -4.6 on InfoTrie's scale. They also gave media headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Supernus Pharmaceuticals.

Some companies that are related to Supernus Pharmaceuticals include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), The Medicines (MDCO), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR) and Pacira Biosciences (PCRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Supernus Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), AbbVie (ABBV), Alibaba Group (BABA), Exelixis (EXEL), GW Pharmaceuticals PLC- (GWPH), Netflix (NFLX), Cara Therapeutics (CARA), Pfizer (PFE) and Corcept Therapeutics (CORT).

Supernus Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Rice Hall James & Associates LLC (1.83%), Renaissance Technologies LLC (1.76%), Rothschild & Co. Asset Management US Inc. (1.40%), Geode Capital Management LLC (1.36%), LSV Asset Management (1.32%) and Loomis Sayles & Co. L P (1.21%). Company insiders that own Supernus Pharmaceuticals stock include Gregory S Patrick, Jack A Khattar, Padmanabh P Bhatt, Stefan KF Schwabe and Victor Vaughn. View Institutional Ownership Trends for Supernus Pharmaceuticals.

SUPN stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Loomis Sayles & Co. L P, Marshall Wace North America L.P., Marshall Wace LLP, Scout Investments Inc., Bank of America Corp DE, Acadian Asset Management LLC and Ingalls & Snyder LLC. View Insider Buying and Selling for Supernus Pharmaceuticals.

SUPN stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Prudential Financial Inc., AJO LP, Knights of Columbus Asset Advisors LLC, Great West Life Assurance Co. Can, Man Group plc, California Public Employees Retirement System and Spark Investment Management LLC. View Insider Buying and Selling for Supernus Pharmaceuticals.

Shares of SUPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SUPN stock can currently be purchased for approximately $22.94.

Supernus Pharmaceuticals has a market capitalization of $1.20 billion and generates $408.90 million in revenue each year. The specialty pharmaceutical company earns $110.99 million in net income (profit) each year or $2.05 on an earnings per share basis. Supernus Pharmaceuticals employs 448 workers across the globe.View Additional Information About Supernus Pharmaceuticals.

The official website for Supernus Pharmaceuticals is http://www.supernus.com/.

Supernus Pharmaceuticals' mailing address is 1550 E GUDE DR, ROCKVILLE MD, 20850. The specialty pharmaceutical company can be reached via phone at 301-838-2500 or via email at [email protected]